Cassava Sciences (SAVA) Stock Price, News & Analysis

Company Overview

Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biotechnology company focused on developing novel therapies for Alzheimer’s disease and other neurodegenerative disorders. Founded in 1998 and headquartered in Austin, Texas, the company originally operated under the name Pain Therapeutics before rebranding to Cassava Sciences in 2015. Its research platform centers on small-molecule compounds designed to restore cognitive function by targeting underlying disease mechanisms rather than simply addressing symptoms.

The company’s lead investigational drug candidate is simufilam, a proprietary small molecule that aims to normalize altered brain proteins implicated in Alzheimer’s pathology. Simufilam is currently being evaluated in late-stage clinical trials, including Phase 3 studies, while Cassava Sciences also conducts biomarker and imaging analyses to support its development program. In addition to its core Alzheimer’s pipeline, the company explores diagnostic approaches to better characterize patient populations and track therapeutic effects over time.

Cassava Sciences operates primarily in the United States but has extended its clinical trial footprint to multiple international sites, collaborating with academic centers and research institutions to advance its programs. The company maintains partnerships with leading universities and contract research organizations to support patient recruitment, data collection and regulatory filings. Through these alliances, Cassava Sciences seeks to accelerate the translation of laboratory discoveries into potential treatment breakthroughs.

The executive leadership team is led by President and Chief Executive Officer Remi Barbier, who has guided the company’s strategic direction since 2004. Under his stewardship, Cassava Sciences has built a specialized research and development organization staffed by neuroscientists, clinicians and regulatory experts. The board of directors includes veteran life-science executives and scientific advisors whose collective experience spans drug discovery, clinical development and commercial strategy in the biopharmaceutical sector.

Key Stats

• Today's Range: $2.10 to $2.36
• 50-Day Range: $1.75 to $2.24
• 52-Week Range: $1.15 to $42.20
• Volume: 1.55 million shs
• Average Volume: 2.79 million shs
• Market Capitalization: $106.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $54.50
• Consensus Rating: Moderate Buy

Cassava Sciences Stock Analysis - MarketRank™

Cassava Sciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 177th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cassava Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cassava Sciences are expected to grow in the coming year, from ($3.97) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cassava Sciences is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cassava Sciences is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cassava Sciences has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.85% of the float of Cassava Sciences has been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 14.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cassava Sciences does not currently pay a dividend.

Dividend Growth

Cassava Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.82

Percentage of Shares Shorted

14.85% of the float of Cassava Sciences has been sold short.

Short Interest Ratio / Days to Cover

Cassava Sciences has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Cassava Sciences has recently decreased by 14.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Cassava Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

Only 8 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cassava Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.40% of the stock of Cassava Sciences is held by insiders.

Percentage Held by Institutions

Only 38.05% of the stock of Cassava Sciences is held by institutions.

SAVA Stock Analysis - Frequently Asked Questions

How have SAVA shares performed this year?

Cassava Sciences' stock was trading at $2.36 at the beginning of the year. Since then, SAVA shares have decreased by 6.4% and is now trading at $2.21.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.48) earnings per share (EPS) for the quarter.

When did Cassava Sciences' stock split?

Shares of Cassava Sciences split on Thursday, December 21st 2023.The 14-10 split was announced on Thursday, December 21st 2023. The newly issued shares were payable to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SAVA
• CIK: 1069530
• Web: www.cassavasciences.com
• Phone: (512) 501-2444
• Fax: 512-501-0414
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cassava Sciences: $54.50
• High Price Target: $107.00
• Low Price Target: $2.00
• Potential Upside/Downside: +2,295.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.34 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.72%
• Return on Assets: -72.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.08
• Quick Ratio: 9.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.03 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 48,310,000
• Free Float: 47,149,000
• Market Cap: $109.91 million
• Optionable: Optionable
• Beta: -2.04